Physician profile
Thea Cross
NPI 1093788044
$280.15
in general payments reported to CMS, 2019-2025
11 companies · $22.41 in 2025
The $22.41 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.71 · 2021: $39.23 · 2022: $47.57 · 2023: $110 · 2024: $13.27 · 2025: $22.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $145.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $80.72 | 2023 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $40.42 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $29.76 | 2020 | |
| Abbvie INC. | $27.49 | 2023-2024 | Vraylar |
| Ge Healthcare | $22.41 | 2025 | |
| Allergan, INC. | $19.63 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $16.76 | 2021 | |
| Supernus Pharmaceuticals, INC. | $15.72 | 2022 | |
| Sk Life Science, INC. | $13.55 | 2023 | |
| Neurelis, INC. | $12.22 | 2022 | |
| Sumitomo Pharma America, INC. | $1.47 | 2023 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thea Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.